Project Grant HT94252410247
Award Date
9/1/24
Completion Date
8/31/26
Dollars Obligated
$790K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Italy
Similar Awards
The Department of Defense (DoD) awarded a $2,536,839 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to New York University (NYU) School of Medicine. The grant, awarded on August 1, 2025, supports the "Advancement of a Novel Therapeutic Strategy for Therapeutic Development in ALS: Targeting the RAGE/DIAPH1 Axis" project. The research aims to transform healthcare for military service members, veterans, and the broader public by investigating...
The University of Massachusetts Medical School was awarded a $836,992 Project Grant by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant, awarded on August 1, 2025, will fund research to investigate the effects of military-associated environmental toxins on motor neurons and glial cells in sporadic amyotrophic lateral sclerosis (ALS). The research aims to transform healthcare for military service members, veterans, and the broader...
This $952,162 federal Project Grant, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research to develop novel, improved adeno-associated virus (AAV) vectors for the treatment of amyotrophic lateral sclerosis (ALS). The award was granted to the University of Massachusetts Medical School (UMass Medical) in Worcester, MA, with a period of performance from August 1, 2025 to July 31, 2027. UMass Medical, as a prominent academic...
The Department of the Army Medical Command awarded a $1,180,437 Project Grant to the University of California, Los Angeles (UCLA) under the Military Medical Research and Development program (CFDA 12.420). The grant supports UCLA's research to evaluate circulating cell-free DNA as a biomarker for diagnosing and tracking the progression of amyotrophic lateral sclerosis (ALS). The award began on March 1, 2024 and is scheduled for completion by February 28, 2026. Through this Project Grant, UCLA...
The Defense Health Agency awarded a $1,397,266 project grant to The University of Queensland under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from March 1, 2023 through February 28, 2026 to develop peptide inhibitors targeting sodium channels for the treatment of Amyotrophic Lateral Sclerosis. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming...
This Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $1,078,882 to the Sanford Burnham Prebys Medical Discovery Institute to conduct advanced chemical engineering research on amyotrophic lateral sclerosis (ALS). The research aims to take a more sophisticated, multimodal approach to understanding the therapeutic actions of donor and host neural stem cells in ALS. The award includes a sub-grant to the J. David...
The federal Project Grant award, valued at $2,490,000.00 and provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, is for the "Development of a VAV2 Antisense Oligonucleotide Therapeutic for ALS" at the University of Southern California (USC). This award, effective March 1, 2025 through February 28, 2027, supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the...
This federal Project Grant award, valued at $1,103,084.00, was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The funding supports the development of a personalized blood-based diagnostic assay for early detection of Amyotrophic Lateral Sclerosis (ALS) at Arizona State University. The university will collaborate with a sub-awardee, Georgetown University, to conduct the research. The project aims to transform healthcare for...
The Defense Health Agency awarded a $1.19 million Project Grant to The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. from May 1, 2023 to April 30, 2026 under the Military Medical Research and Development program (CFDA 12.420). The grant funds research into targeting excessive sphingolipid synthesis for treatment of amyotrophic lateral sclerosis (ALS) being conducted by Dr. Teresa M. Dunn of the Uniformed Services University of the Health Sciences. Dr. Dunn is...
The Department of Defense's Defense Health Agency awarded a $1,035,460 Project Grant to Brigham & Women's Hospital Inc. to conduct research on "TREATMENT OF ALS BY NASAL ADMINISTRATION OF ANTI-CD3 MONOCLONAL ANTIBODY TO MODULATE INFLAMMATORY MICROGLIA AND PREVENT MOTOR NEURON DEGENERATION". This grant, funded under the Military Medical Research and Development program (CFDA 12.420), aims to develop a new treatment approach for amyotrophic lateral sclerosis (ALS) by modulating...